The function of AFP in adult humans is unknown. AFP is the most abundant plasma protein found in the human fetus. In the fetus, AFP is produced by both the liver and the yolk sac. It is believed to function as a carrier protein (similar to albumin) that transports materials such as fatty acids to cells.[13] Maternal plasma levels peak near the end of the first trimester, and begin decreasing prenatally at that time, then decrease rapidly after birth. Normal adult levels in the newborn are usually reached by the age of 8 to 12 months. While the function in humans is unknown, in rodents it binds
estradiol to prevent the transport of this hormone across the
placenta to the fetus. The main function of this is to prevent the
virilization of female fetuses. As human AFP does not bind estrogen, its function in humans is less clear.[14]
The rodent AFP system can be overridden with massive injections of estrogen, which overwhelm the AFP system and will masculinize the fetus. The masculinizing effect of estrogens may seem counter-intuitive since estrogens are critical for the proper development of female secondary characteristics during puberty. However, this is not the case prenatally.
Gonadal hormones from the testes, such as
testosterone and
anti-Müllerian hormone, are required to cause development of a phenotypic male. Without these hormones, the fetus will develop into a phenotypic female even if genetically
XY. The conversion of testosterone into estradiol by
aromatase in many tissues may be an important step in masculinization of that tissue.[15][16] Masculinization of the brain is thought to occur both by conversion of testosterone into estradiol by aromatase, but also by
de novo synthesis of estrogens within the brain.[17][18] Thus, AFP may protect the fetus from maternal estradiol that would otherwise have a masculinizing effect on the fetus, but its exact role is still controversial.
In pregnant women, fetal AFP levels can be monitored in the urine of the pregnant woman. Since AFP is quickly cleared from the mother's serum via her kidneys, maternal urine AFP correlates with fetal serum levels, although the maternal urine level is much lower than the fetal serum level. AFP levels rise until about week 32. Maternal serum alpha-fetoprotein (MSAFP) screening is performed at 16 to 18 weeks of gestation.[19] If MSAFP levels indicate an anomaly,
amniocentesis may be offered to the patient.
Infants
The normal range of AFP for adults and children is variously reported as under 50, under 10, or under 5 ng/mL.[20][21] At birth, normal infants have AFP levels four or more orders of magnitude above this normal range, that decreases to a normal range over the first year of life.[22][23][24][25][26][27]
During this time, the normal range of AFP levels spans approximately two orders of magnitude.[24] Correct evaluation of abnormal AFP levels in infants must take into account these normal patterns.[24]
Very high AFP levels may be subject to hooking (see
Tumor marker), which results in the level being reported significantly lower than the actual concentration.[28] This is important for analysis of a series of AFP tumor marker tests, e.g. in the context of post-treatment early surveillance of cancer survivors, where the rate of decrease of AFP has diagnostic value.
Measurement of AFP is generally used in two clinical contexts. First, it is measured in pregnant women through the analysis of maternal
blood or
amniotic fluid as a
screening test for certain developmental abnormalities, such as
aneuploidy. Second, serum AFP level is elevated in people with certain tumors, and so it is used as a
biomarker to follow these diseases. Some of these diseases are listed below:
Developmental birth defects associated with elevated AFP
A peptide derived from AFP that is referred to as
AFPep is claimed to possess anti-cancer properties.[35]
In the treatment of
testicular cancer it is paramount to differentiate
seminomatous and
nonseminomatous tumors. This is typically done pathologically after removal of the testicle and confirmed by tumor markers. However, if the pathology is pure
seminoma, if the AFP is elevated, the tumor is treated as a nonseminomatous tumor because it contains yolk sac (nonseminomatous) components.[36]
^Ball D, Rose E, Alpert E (March 1992). "Alpha-fetoprotein levels in normal adults". The American Journal of the Medical Sciences. 303 (3): 157–9.
doi:
10.1097/00000441-199203000-00004.
PMID1375809.
^Sizaret P, Martel N, Tuyns A, Reynaud S (February 1977). "Mean alpha-fetoprotein values of 1,333 males over 15 years by age groups". Digestion. 15 (2): 97–103.
doi:
10.1159/000197990.
PMID65304.
^Blohm ME, Vesterling-Hörner D, Calaminus G, Göbel U (1998). "Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age". Pediatric Hematology and Oncology. 15 (2): 135–42.
doi:
10.3109/08880019809167228.
PMID9592840.
^Ohama K, Nagase H, Ogino K, Tsuchida K, Tanaka M, Kubo M, Horita S, Kawakami K, Ohmori M (October 1997). "Alpha-fetoprotein (AFP) levels in normal children". European Journal of Pediatric Surgery. 7 (5): 267–9.
doi:
10.1055/s-2008-1071168.
PMID9402482.
S2CID260137699.
^Bader D, Riskin A, Vafsi O, Tamir A, Peskin B, Israel N, Merksamer R, Dar H, David M (November 2004). "Alpha-fetoprotein in the early neonatal period--a large study and review of the literature". Clinica Chimica Acta. 349 (1–2): 15–23.
doi:
10.1016/j.cccn.2004.06.020.
PMID15469851.
^Wu JT, Roan Y, Knight JA (1985). "Serum levels of AFP in normal infants: their clinical and physiological significance". In Mizejewski GJ, Porter I (eds.). Alfa-Fetoprotein and Congenital Disorders. New York: Academic Press. pp. 111–122.
^Szabó M, Veress L, Münnich A, Papp Z (September 1990). "[Alpha fetoprotein concentration in the amniotic fluid in normal pregnancy and in pregnancy complicated by fetal anomaly]". Orvosi Hetilap (in Hungarian). 131 (39): 2139–42.
PMID1699194.
^Rosen T, D'Alton ME (December 2005). "Down syndrome screening in the first and second trimesters: what do the data show?". Seminars in Perinatology. 29 (6): 367–75.
doi:
10.1053/j.semperi.2006.01.001.
PMID16533649.
^
abcLe, Tao. First Aid for the USMLE Step 1 2013. New York: McGraw-Hill Medical, 2013. Print.
^Bredaki FE, Poon LC, Birdir C, Escalante D, Nicolaides KH (2012). "First-trimester screening for neural tube defects using alpha-fetoprotein". Fetal Diagnosis and Therapy. 31 (2): 109–14.
doi:
10.1159/000335677.
PMID22377693.
S2CID57465.
^Ertle JM, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, Gerken G, Schlaak JF (2013). "A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma". Digestion. 87 (2): 121–31.
doi:
10.1159/000346080.
PMID23406785.
S2CID25266129.
Nahon JL (1987). "The regulation of albumin and alpha-fetoprotein gene expression in mammals". Biochimie. 69 (5): 445–59.
doi:
10.1016/0300-9084(87)90082-4.
PMID2445387.
Tilghman SM (1989). "The structure and regulation of the alpha-fetoprotein and albumin genes". Oxford Surveys on Eukaryotic Genes. 2: 160–206.
PMID2474300.
Mizejewski GJ (2003). "Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy". Expert Review of Anticancer Therapy. 2 (6): 709–35.
doi:
10.1586/14737140.2.6.709.
PMID12503217.
S2CID8321005.
Yachnin S, Hsu R, Heinrikson RL, Miller JB (1977). "Studies on human alpha-fetoprotein. Isolation and characterization of monomeric and polymeric forms and amino-terminal sequence analysis". Biochimica et Biophysica Acta. 493 (2): 418–28.
doi:
10.1016/0005-2795(77)90198-2.
PMID70228.
Aoyagi Y, Ikenaka T, Ichida F (1977). "Comparative chemical structures of human alpha-fetoproteins from fetal serum and from ascites fluid of a patient with hepatoma". Cancer Research. 37 (10): 3663–7.
PMID71198.
Aoyagi Y, Ikenaka T, Ichida F (1978). "Copper(II)-binding ability of human alpha-fetoprotein". Cancer Research. 38 (10): 3483–6.
PMID80265.
Aoyagi Y, Ikenaka T, Ichida F (1979). "alpha-Fetoprotein as a carrier protein in plasma and its bilirubin-binding ability". Cancer Research. 39 (9): 3571–4.
PMID89900.
Torres JM, Anel A, Uriel J (1992). "Alpha-fetoprotein-mediated uptake of fatty acids by human T lymphocytes". Journal of Cellular Physiology. 150 (3): 456–62.
doi:
10.1002/jcp.1041500305.
PMID1371512.
S2CID32015210.
Greenberg F, Faucett A, Rose E, et al. (1992). "Congenital deficiency of alpha-fetoprotein". American Journal of Obstetrics and Gynecology. 167 (2): 509–11.
doi:
10.1016/S0002-9378(11)91441-0.
PMID1379776.
Bansal V, Kumari K, Dixit A, Sahib MK (1991). "Interaction of human alpha fetoprotein with bilirubin". Indian Journal of Experimental Biology. 28 (7): 697–8.
PMID1703124.
Pucci P, Siciliano R, Malorni A, et al. (1991). "Human alpha-fetoprotein primary structure: a mass spectrometric study". Biochemistry. 30 (20): 5061–6.
doi:
10.1021/bi00234a032.
PMID1709810.
Gibbs PE, Zielinski R, Boyd C, Dugaiczyk A (1987). "Structure, polymorphism, and novel repeated DNA elements revealed by a complete sequence of the human alpha-fetoprotein gene". Biochemistry. 26 (5): 1332–43.
doi:
10.1021/bi00379a020.
PMID2436661.
Ruoslahti E, Pihko H, Vaheri A, et al. (1975). "Alpha fetoprotein: structure and expression in man and inbred mouse strains under normal conditions and liver injury". Johns Hopkins Med. J. Suppl. 3: 249–55.
PMID4138095.
Urano Y, Sakai M, Watanabe K, Tamaoki T (1985). "Tandem arrangement of the albumin and alpha-fetoprotein genes in the human genome". Gene. 32 (3): 255–61.
doi:
10.1016/0378-1119(84)90001-5.
PMID6085063.
Beattie WG, Dugaiczyk A (1983). "Structure and evolution of human alpha-fetoprotein deduced from partial sequence of cloned cDNA". Gene. 20 (3): 415–22.
doi:
10.1016/0378-1119(82)90210-4.
PMID6187626.